Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis
Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis
Not yet recruiting · NCT05105958 · Registry updated 2025-01-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Not yet recruiting | Phase 2 | 2025-01-28 | NCT05105958 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cantonal Hospital of St. Gallen | 27 |
| University Hospital, Geneva | 108 |
| University of Bern | 126 |
| University of Lausanne Hospitals | 26 |
| University of Zurich | 188 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Kantonsspital St. Gallen | Sankt Gallen | Switzerland | 20 |
| University Hospital Bern | Bern | Switzerland | 9 |
| University Hospital Geneva | Geneva | Switzerland | 3 |
| University Hospital Lausanne | Lausanne | Switzerland | 4 |
| University Hospital Zurich | Zurich | Switzerland | 25 |